Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Moodys
Cerilliant
Express Scripts
AstraZeneca
Cantor Fitzgerald
Medtronic
Federal Trade Commission
Merck
US Department of Justice

Generated: August 23, 2017

DrugPatentWatch Database Preview

Patents Expiring in April 2029

« Back to Dashboard
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxosmithkline Cons
NICORETTE
nicotine polacrilex
TROCHE/LOZENGE;ORAL022360-002May 18, 2009OTCYesYes► Subscribe► SubscribeY
Glaxosmithkline Cons
NICORETTE
nicotine polacrilex
TROCHE/LOZENGE;ORAL022360-001May 18, 2009OTCYesNo► Subscribe► SubscribeY
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe TREATMENT OF HYPERURICEMIA
Gilead
ATRIPLA
efavirenz; emtricitabine; tenofovir disoproxil fumarate
TABLET;ORAL021937-001Jul 12, 2006RXYesYes► Subscribe► SubscribeY
Tesaro Inc
ZEJULA
niraparib tosylate
CAPSULE;ORAL208447-001Mar 27, 2017RXYesYes► Subscribe► SubscribeY
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes► Subscribe► Subscribe TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Healthtrust
US Department of Justice
Accenture
Covington
QuintilesIMS
US Army
Cipla
Johnson and Johnson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot